Piramal Pharma Solutions (PPS), a global Contract Development and Manufacturing Organisation (CDMO), has announced an $80 million investment to expand its manufacturing site in Lexington, Kentucky. The facility, which specialises in sterile injectable drug production, will see its capacity significantly enhanced to meet growing market demand. The investment is being financed through bank loans and internal funds, with completion expected by the first quarter of 2027.
The expansion of the Lexington site will add 24,000 square feet of manufacturing space, alongside new laboratory facilities and advanced machinery. Among the new equipment to be installed are a filling line, two commercial-size lyophilisers, a specialist capping machine, and an external vial washer. These upgrades will enable the site to increase its production capacity from the current 104 batches per year to over 240 annual batches once the expansion is complete.
Piramal Pharma Solutions’ Lexington site plays a central role in the company’s integrated Antibody-Drug Conjugate (ADC) programme, known as ADCelerate™, which supports the development and manufacturing of complex biologic therapies. The increased capacity and new equipment are expected to strengthen Piramal’s position in the rapidly growing injectables market, which is projected to exceed $20 billion by 2028.
Nandini Piramal, Chairperson of Piramal Pharma Ltd, stated: “This expansion represents a strategic investment in the future of Piramal Pharma. By filling the commercial manufacturing gap, the Lexington site will gain access to the growing injectables market and establish itself as a key player in the sector.”
The injectables market has been expanding rapidly due to advancements in scientific research and innovation, with demand for sterile injectable treatments outpacing supply. Peter DeYoung, CEO of Global Pharma at Piramal Pharma Solutions, explained the company’s commitment to meeting this growing demand: “This expansion will significantly enhance the capacity and capabilities of our Lexington facility, positioning Piramal Pharma as a comprehensive partner across the entire product life cycle. It will also allow us to provide treatment solutions to more patients worldwide.”
The expansion is also expected to bring significant economic benefits to the local area. Over 40 full-time jobs will be created as a result of the investment, boosting the local economy and providing new opportunities for residents in Lexington.
Kentucky Governor Andy Beshear welcomed the investment, highlighting the state’s favourable business environment. He commented: “Kentucky’s business-friendly climate, prime location, and access to resources make it an ideal destination for companies to locate, expand, and thrive. The decision by Piramal Pharma Solutions to expand and reinvest here is a testament to their trust in what this great state has to offer.”
Bob Quick, President and CEO of Commerce Lexington Inc., also praised the move, noting its positive impact on the region: “Piramal Pharma’s decision to expand its Lexington operations is a significant step forward for our region’s economic growth. This investment underscores Lexington’s position as a prime location for innovative companies to grow and thrive. We look forward to the positive impact this expansion will have on our local economy and the new opportunities it will create for our residents.”
The expansion marks a key milestone in Piramal Pharma’s growth strategy, strengthening its ability to provide high-quality, science-based solutions to its global clients while reinforcing its commitment to the local workforce and economy. For more information, visit: www.piramalpharmasolutions.com
